Trial
NCT02523768
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
—
Condition
Glomerulonephritis
Intervention
ATG-F
Why stopped
Difficulties for recruting patients
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-20